<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166045</url>
  </required_header>
  <id_info>
    <org_study_id>CRD-01-1282-01</org_study_id>
    <nct_id>NCT04166045</nct_id>
  </id_info>
  <brief_title>Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain</brief_title>
  <official_title>Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranova, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranova, L.L.C.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to&#xD;
      that of a sham control treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Actual">April 29, 2021</completion_date>
  <primary_completion_date type="Actual">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain score</measure>
    <time_frame>4 months</time_frame>
    <description>We will also assess the change in migraine pain before versus after treatment with the 100-mm Visual Analogue Scale (VAS), which is a continuum scale that patients can quantify their pain from none (0 mm) to extreme (100 mm) for both treatment sites. The mean score for each patient cohort will be calculated. We will also perform a sub analysis on women versus men.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects who are responders</measure>
    <time_frame>4 months</time_frame>
    <description>For each subject treatment effectiveness will be assessed by both achieving pain relief (if the pain decreases from a 4-point visual rating scale (VRS) of 'severe' or 'moderate' at pre-treatment to 'mild' or 'none' at 120-min post-treatment) or pain-free ('none') status. The percent of subjects that experience a significant reduction in pain relief score (VRS) will be calculated for the verum and sham treatment sites.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment at the bicep location</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment at the hand location</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment Location</intervention_name>
    <description>The device applies transcutaneous electrical nerve stimulation to the bicep</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verum Treatment Location</intervention_name>
    <description>The device applies transcutaneous electrical nerve stimulation to the hand</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-100 years, inclusive&#xD;
&#xD;
          -  Diagnosis of episodic migraine with and without aura per International Headache&#xD;
             Society diagnostic criteria&#xD;
&#xD;
          -  4-14 migraine days per month&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Demonstrates no contraindication to the use of electrical nerve stimulation&#xD;
&#xD;
          -  Capable and willing to follow all study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant or breastfeeding, pregnant within the past 6 months or intends to&#xD;
             become pregnant during the enrollment period&#xD;
&#xD;
          -  Diagnosis of chronic migraine or other forms of primary or secondary headache&#xD;
             disorders, including medication overuse headache per International Headache Society&#xD;
             diagnostic criteria&#xD;
&#xD;
          -  Any medical condition that would, in the opinion of the investigator, make the subject&#xD;
             ineligible&#xD;
&#xD;
          -  Has received botulinum toxin injections within the past 3 months&#xD;
&#xD;
          -  Is currently implanted with an electrical and/or neurostimulator devic, including but&#xD;
             not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, sacral&#xD;
             stimulator, bone growth stimulator, or cochlear implant&#xD;
&#xD;
          -  Use of investigational drug/device therapy within the past 4 weeks&#xD;
&#xD;
          -  Deemed unsuitable for enrollment in study by the investigator based on subjects'&#xD;
             history or physical examination (including bleeding disorders, anticoagulant&#xD;
             medications and peripheral neuropathy)&#xD;
&#xD;
          -  No changes in preventive medications (or other medications determined to potentially&#xD;
             interfere with the study) in the previous 30 days and no intent to change it during&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

